Syros (SYRS): Market Capitalization-to-Revenue Ratio
Syros Pharmaceuticals (SYRS) is pursuing expansion in the onco-hematology segment through the implementation of tamibarotene inhibitors. This P/S chart illustrates the asset's market valuation, where the 8.20 level indicates the parameter's status. The company reprograms tumor cell functions for therapy, although it is currently conducting a rigorous restructuring of its R&D pipeline and implementing capital preservation measures following a series of clinical failures.
Analytical breakdowns for Syros (SYRS)
- stock value and consensus price forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Syros Pharmaceuticals|SYRS - Long-Term Debt to Capital|Current Liabilities to Capital Syros Pharmaceuticals, Inc|SYRS - Company Total Debt|Debts to Book Capitalization Syros|SYRS - Company Long-Term Liabilities|Amount of Current Liabilities Syros Pharmaceuticals|Interim Coverage Ratio syros.com
- business earnings and investment ratios data:
SYRS - Net Profit|Future Profit Syros Pharmaceuticals|SYRS - P/E Multiple|Forward P/E Multiple Syros Pharmaceuticals Inc.|SYRS - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Syros|SYRS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Syros Pharmaceuticals|SYRS - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months syros.com|SYRS - Net earnings per share growth this year|Expected net earnings per share growth next year Syros Pharmaceuticals
- issuer revenue and sales details:
Summary company analytics:SYRS syros.com
Syros Pharmaceuticals (SYRS) focuses on expansion into oncohematology through the development of tamibarotene inhibitors, rendering current revenue secondary to the pipeline's potential. This price/sales ratio reflects market capitalization relative to sales volumes, allowing investors to assess the extent of priced-in future growth expectations through the prism of the business's current value on the chart.
Who Syros Pharmaceuticals competes with
P/S Multiple Tempus AI (TEM)|Price-to-Revenue Ratio Qiagen QGEN|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Avidity Corp (RNA) - Market Cap to Revenue|CRSP: P/S Multiple|genedx.com (WGS) - P/S Multiple|RARE (Ultragenyx) - P/S Multiple|Market Cap to Revenue Beam Therapeutics Inc (BEAM)|P/S Multiple SRPT|TWST - Price to Sales|10x Genomics, Inc. - Market Cap to Revenue|P/S Multiple intelliatx.com NTLA|STOK: Market Cap to Revenue|BioLife Solutions Inc - Market Cap to Sales Volume|WVE: P/S Multiple|MAZE - Price-to-Revenue Coefficient|SION (Sionna Therapeutics Inc) - P/S Multiple|Market Cap to Revenue primemedicine.com (PRME)|P/S Multiple TSHA|P/S Multiple uniQure NV (QURE)|Price-to-Revenue Ratio MeiraGTx PLC MGTX|REGENXBIO Corp - Price-to-Revenue Ratio|SLDB - Price-to-Revenue Ratio|Price-to-Revenue Coefficient ocugen.com OCGN|PacBio (PACB) - Price-to-Revenue Ratio|BNTC - Price-to-Revenue Coefficient|Market Cap to Revenue DSGN|Price to Sales Rocket Corp RCKT|Price-to-Revenue Ratio 4D Molecular Therapeutics (FDMT)|LXEO (lexeotx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Korro Bio KRRO|Price-to-Revenue Coefficient Editas Medicine Inc (EDIT)|Silence Therapeutics Inc. - P/S Multiple|PRQR (ProQR Therapeutics N.V.) - Market Cap to Revenue Ratio|codexis.com (CDXS) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio SGMO|NAUT (Nautilus Biotechnology, Inc.) - P/S Multiple|P/S Multiple Metagenomi Inc.|Price-to-Revenue Ratio Precision BioSciences, Inc. (DTIL)|Price-to-Revenue Coefficient generationbio.com|Boundless Bio, Inc. - Market Cap to Revenue|Exicure Inc. (XCUR) - Price to Sales|IMNN - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio PHIO (Phio Pharmaceuticals)|mustangbio.com (MBIO) - Price-to-Revenue Ratio|Price to Sales TransCode Therapeutics, Inc. (RNAZ)|Price-to-Revenue Ratio Bionano Genomics Inc.|adnas.com (APDN) - Price-to-Revenue Coefficient|Market Cap to Revenue BLUE (bluebird bio)|IPA (immunoprecise.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Omega OMGA|OMIC (Singular Genomics Corp) - Price-to-Sales Ratio|Regulus Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio TBIO (telesisbio.com)|TCON: P/S Multiple|Unity Biotechnology Inc. (UBX) - P/S Multiple
